Pankaj Patel's Cadila receives approval from USFDA, stock sizzles
Shital Jibhe / 18 Jan 2017
One of the leading pharmaceutical companies in India and also a global healthcare provider, Ahmedabad-based Zydus Cadila Healthcare has received a final approval from the US Food and Drug Administration (USFDA) to market Methotrexate Tablets USP, 2.5 mg.
One of the leading pharmaceutical companies in India and also a global healthcare provider, Ahmedabad-based Zydus Cadila Healthcare has received a final approval from the US Food and Drug Administration (USFDA) to market Methotrexate Tablets USP, 2.5 mg. The drug which is helpful in curing leukemia, lymphoma, breast cancer, lung cancer and other cancers, will be produced at group formulation manufacturing plant in Ahmedabad Pharma Special Economic Zone (SEZ).
Meanwhile, Zydus Cadila Healthcare is also trending for its stock gain of 1.63 per cent on Wednesday. The stock of the company is trading with a Simple Moving Average (SMA) of 364.38. In the last one year, the stock has surged by 18.09 per cent.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.